Company profile for Opthea

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Opthea is committed to improving vision in patients suffering from retinal eye diseases. We are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in conjunction with existing standard of care anti-VEGF-A therapies. OPT-302 has the potential to address the unmet medical need of wet AMD and DME patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilit...
Opthea is committed to improving vision in patients suffering from retinal eye diseases. We are developing a novel therapeutic called OPT-302, a VEGF-C/D ‘trap’, to be used in conjunction with existing standard of care anti-VEGF-A therapies. OPT-302 has the potential to address the unmet medical need of wet AMD and DME patients, many of whom respond sub-optimally or become refractory to existing therapies for these debilitating diseases. We are advancing the clinical development of OPT-302 in Phase 2 wet AMD and DME clinical trials.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Australia
Address
Address
Suite 0403, Level 4, 650 Chapel Street, South Yarra, Victoria 3141
Telephone
Telephone
+613 9826 0399
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
Opthea Cuts 85% of Staff, Including CEO
Opthea Cuts 85% of Staff, Including CEO

19 Aug 2025

// FIERCE BIOTECH

https://www.fiercebiotech.com/biotech/opthea-still-reeling-eye-disease-flops-ramps-layoffs-85-and-loses-ceo

FIERCE BIOTECH
19 Aug 2025
Opthea Provides Corporate Update
Opthea Provides Corporate Update

18 Aug 2025

// GLOBENEWSWIRE

https://www.globenewswire.com/news-release/2025/08/18/3135369/0/en/Opthea-Provides-Corporate-Update.html

GLOBENEWSWIRE
18 Aug 2025

https://www.fiercebiotech.com/biotech/opthea-lays-65-staff-after-back-back-phase-3-flops

FIERCE BIOTECH
11 Apr 2025

https://www.globenewswire.com/news-release/2025/03/31/3051929/0/en/Opthea-Announces-Decision-to-Discontinue-Wet-AMD-Trials.html

GLOBENEWSWIRE
31 Mar 2025

https://www.globenewswire.com/news-release/2025/03/24/3047520/0/en/Opthea-Announces-COAST-Phase-3-Trial-Topline-Results.html

GLOBENEWSWIRE
24 Mar 2025

https://www.globenewswire.com//news-release/2025/03/03/3035446/0/en/Opthea-Announces-Phase-2b-Wet-AMD-Publication.html

GLOBENEWSWIRE
03 Mar 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty